"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
Descriptor ID |
D014408
|
MeSH Number(s) |
D23.101.140
|
Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 3 | 6 |
1995 | 1 | 0 | 1 |
1996 | 3 | 2 | 5 |
1997 | 3 | 7 | 10 |
1998 | 2 | 4 | 6 |
1999 | 2 | 8 | 10 |
2000 | 3 | 11 | 14 |
2001 | 3 | 11 | 14 |
2002 | 9 | 5 | 14 |
2003 | 6 | 12 | 18 |
2004 | 12 | 13 | 25 |
2005 | 13 | 9 | 22 |
2006 | 15 | 13 | 28 |
2007 | 15 | 13 | 28 |
2008 | 24 | 17 | 41 |
2009 | 21 | 25 | 46 |
2010 | 14 | 20 | 34 |
2011 | 25 | 29 | 54 |
2012 | 30 | 18 | 48 |
2013 | 28 | 30 | 58 |
2014 | 17 | 23 | 40 |
2015 | 30 | 30 | 60 |
2016 | 21 | 34 | 55 |
2017 | 30 | 28 | 58 |
2018 | 29 | 35 | 64 |
2019 | 51 | 31 | 82 |
2020 | 42 | 26 | 68 |
2021 | 24 | 32 | 56 |
2022 | 2 | 26 | 28 |
2023 | 0 | 17 | 17 |
2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma. Adv Anat Pathol. 2024 May 01; 31(3):202-205.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
-
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
-
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer. J Appl Lab Med. 2024 Jan 03; 9(1):76-91.
-
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer Discov. 2023 12 12; 13(12):2532-2547.
-
Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506.
-
Diagnostic Performance of Magnetic Resonance Imaging for Pediatric Ovarian Neoplasms: A Multi-Institutional Review. J Pediatr Adolesc Gynecol. 2024 Apr; 37(2):192-197.
-
Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer. JAMA Netw Open. 2023 Nov 01; 6(11):e2343512.
-
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.